Charles River Laboratories International (NYSE:CRL) Sets New 1-Year High – What’s Next?

Posted by Francis Steltz on Aug 17th, 2026

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report)’s share price hit a new 52-week high during trading on Monday . The company traded as high as $288.64 and last traded at $288.4150, with a volume of 350686 shares changing hands. The stock had previously closed at $280.05.

Wall Street Analyst Weigh In

CRL has been the subject of a number of research reports. Royal Bank Of Canada increased their price objective on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research note on Monday, August 10th. Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. TD Cowen raised their target price on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Finally, BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $255.65.

Get Our Latest Stock Report on CRL

Charles River Laboratories International Price Performance

The business has a fifty day moving average of $224.87 and a two-hundred day moving average of $191.11. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm has a market capitalization of $13.74 billion, a price-to-earnings ratio of -59.36, a price-to-earnings-growth ratio of 2.90 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same quarter last year, the firm posted $3.12 EPS. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, EVP Victoria L. Creamer sold 4,179 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president owned 30,051 shares in the company, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shannon M. Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,264,241. The trade was a 51.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 129,817 shares of company stock worth $31,774,935. 1.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CRL. Cardinal Capital Management grew its stake in shares of Charles River Laboratories International by 0.6% during the 4th quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after acquiring an additional 62 shares during the period. Asset Management One Co. Ltd. raised its stake in Charles River Laboratories International by 4.0% during the 4th quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock worth $375,000 after acquiring an additional 71 shares during the period. Glenmede Trust Co. NA lifted its holdings in Charles River Laboratories International by 2.8% during the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 73 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its position in shares of Charles River Laboratories International by 1.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after purchasing an additional 80 shares during the period. Finally, Advisory Services Network LLC boosted its position in shares of Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after purchasing an additional 83 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.